Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test

Anti-Cancer Drugs

Volumn 16, Issue 5, 2005, Pages 525-531

  Nagai, Nobutaka ^a   Minamikawa, Kazuhiko ^b   Mukai, Keiji ^a   Hirata, Eiji ^a   Komatsu, Masaaki ^a   Kobayashi, Hisayuki ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Nitta Gelatin Inc   (Japan)

Author keywords

Chemosensitivity test; Collagen gel droplet culture drug sensitivity test; Ovarian cancer; Uterine cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; COLLAGEN GEL; DOCETAXEL; PACLITAXEL;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURETTAGE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LINEAR REGRESSION ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PUNCH BIOPSY; UTERINE CERVIX CANCER; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 18844416174     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200506000-00008     Document Type: Article

References (41)

1. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997; 75:230-235.
2. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 1998; 91:783-792.
3. Laframboise S, Chapman W, McLaughlin J, Andrulis IL. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J 2000; 6:302-308.
4. Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JG, Look MP, Foekens JA, et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21 BAX and BCL-2. Br J Cancer 2001; 85:1359-1367.
5. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer 1999; 35:1214-1219.
6. Lang T, Daxenbichler G, Marth C. Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. Anticancer Res 1994; 14:1871-1874.
7. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 1994; 54:1335-1339.
8. Germain I, Tetu B, Brisson J, Mondor M, Cherian MG. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol 1996; 15:54-62.
9. Von Hoff DD. He's not going to talk about in vitro predictive assay again, is he? J Natl Cancer Inst 1990; 82:96-101.
10. Tanigawa N, Morimoto H, Dohmae N, Shimomatsuya T, Takahashi K, Muraoka R. In vitro growth ability and chemosensitivity of gastric and colorectal cancer cells assessed with the human tumor clonogenic assay and thymidine incorporation assay. Eur J Cancer 1992; 28:31-34.
11. Fruehauf JP, Bosanquet AG. In vitro determination of drug response: a discussion of clinical applications. Cancer Principle Pract Oncol 1992; 7:12.
12. Carmichael J, De Graff WG, Gazder AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942.
13. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1987; 4:389-398.
14. Furukawa T, Kubota T, Hoffman RM. Clinical application of the histoculture drug response assay. Clin Cancer Res 1995; 1:305-311.
15. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 2000; 20:2049-2054.
16. Kochli OR, Sevin BU, Averette HE, Schar G, Haller V. Overview of currently used chemosensitivity test systems in gynecologic malignancies and breast cancer. Contrib Gynecol Obstet 1994; 19:12-23.
17. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, et al. An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol 1997; 11:449-455.
18. Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, et al. Examination of in vitro chemosensitivity test using collagen gel droplet culture method employing colorimetric endpoint quantification. Jpn J Cancer Res 2001; 92:1-8.
19. Young RC, Von Hoff DD, Gormbey P, Makuch R, Cassidy J, Howser D, et al. cis-Dichlorodiammineplatinum (II) for the treatment of advanced ovarian cancer. Cancer Treat Res 1979; 63:1539-1544.
20. Taylor AE, Wiltshaw E, Gore ME, Fryatt I, Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1979; 12:2066-2070.
21. Kavanagh JJ. Docetaxel in the treatment of ovarian cancer. Oncology 2002; 16:73-81.
22. Thigpen T, Shingleton H, Homesley H, LaGasse L, Blessing J. cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 1979; 63:1549-1555.
23. Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1979; 18:11-24.
24. Mc Guire WP, Arseneau JC, Blessing JA, DiSaia PJ, Hatch KD, Given Jr FT, et al. A randomized comparative trial of carboplatin and iproplation in advanced squamous carcinoma of the uterine cervix-a Gynecologic Oncology Group Study. J Clin Oncol 1989; 7:1462-1468.
25. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulas G. Paclitaxel has moderate activity In squamous cervix cancer. A Gynecologic Oncology Group Study. J Clin Oncol 1996; 14:792-795.
26. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Flowler Jr WC, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19:1275-1278.
27. Kudelka AP, Verschraegen CF, Levy T, Edwards CL, Fishman A, Freeman RS, et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1996; 7:398-401.
28. Vallejo CT, Machiavelli MR, Pe'rez J, Romero AO, Bologna F, Vicente H, et al. Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical cancer. Am J Clin Oncol 2003; 26:477-482.
29. Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study. Gynecol Oncol 1989; 33:68-70.
30. Green JB, Green S, Alberts DS, O'Toole R, Surwit EA, Noltimier JW. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990; 75:696-700.
31. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol 1996; 62:278-281.
32. Andreotti PE, Cree IT, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
33. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996; 7:630-635.
34. Sinha DK, White CJ. Collagen gel culture of rat mammary tumor cells as an assay system for determination of therapeutic efficacy of chemotherapeutic agents. In Vitro Cell Dev Biol 1988; 24:525-529.
35. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983; 43:1926-1931.
36. Freeman AE, Hoffman RM. In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 1986; 83:2694-2698.
37. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern P, Hoffman RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci USA 1987; 84:5029-5033.
38. Ohyama S, Tanaka LVL, Yonemura Y, Kinoshita K, Miyazaki I, Sasaki T. In vitro chemosensitivity test of human gastric carcinomas using collagen gel matrix. Jpn J Cancer Res 1991; 82:607-612.
39. Hoffman RM, Connors KM, Meerson-Monosov AZ, Herrera H, Price JH. A general native-state method for determination of proliferation capacity of human normal and tumor tissues in vitro. Proc Natl Acad Sci USA 1989; 86:2013-2017.
40. Inaba M, Tashiro T, Ohnishi Y, Tanisaka K, Kobayashi H, Koezuka M. In vitro-in vivo correlation in anticancer drug-sensitivity test using AUC-based concentrations and collagen gel droplet embedded culture. Oncology 1996; 53:250-257.
41. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs 1997; 8:541-548.